{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:13Z","timestamp":1792787833486,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T00:00:00Z","timestamp":1782345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development","award":["#09-009"],"award-info":[{"award-number":["#09-009"]}],"id":[{"id":"https:\/\/ror.org\/05eq41471","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development","award":["#09-009"],"award-info":[{"award-number":["#09-009"]}],"id":[{"id":"https:\/\/ror.org\/05eq41471","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development","award":["#09-009"],"award-info":[{"award-number":["#09-009"]}],"id":[{"id":"https:\/\/ror.org\/05eq41471","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development","award":["#09-009"],"award-info":[{"award-number":["#09-009"]}],"id":[{"id":"https:\/\/ror.org\/05eq41471","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development","award":["#09-009"],"award-info":[{"award-number":["#09-009"]}],"id":[{"id":"https:\/\/ror.org\/05eq41471","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development","award":["#09-009"],"award-info":[{"award-number":["#09-009"]}],"id":[{"id":"https:\/\/ror.org\/05eq41471","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Department of Veterans Affairs, Veterans Health Administration, Health Services Research and Development","award":["#09-009"],"award-info":[{"award-number":["#09-009"]}],"id":[{"id":"https:\/\/ror.org\/05eq41471","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Whole breast moderate hypofractionation is recommended for most breast cancer populations to improve survival and reduce recurrence. Whole breast ultra-hypofractionation and external beam accelerated partial breast irradiation (APBI) may reduce toxicity while maintaining benefits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MEDLINE and Embase searches through March 2024 identified randomized controlled trials (RCTs) evaluating adjuvant external beam hypofractionated radiation therapy for breast cancer. Eligibility and risk of bias (RoB) were assessed by two reviewers and required consensus. For prioritized outcomes (e.g., overall survival, acute toxicity), certainty of evidence was assessed using GRADE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-nine RCTs compared whole breast moderate hypofractionation vs. conventional radiation (CFRT;\n                      <jats:italic>k<\/jats:italic>\n                      \u2009=\u200925); whole breast ultra-hypofractionation vs. moderate hypofractionation or CFRT (\n                      <jats:italic>k<\/jats:italic>\n                      \u2009=\u20098); or external beam APBI vs. whole breast radiation (\n                      <jats:italic>k<\/jats:italic>\n                      \u2009=\u20096). For all comparisons, there were low RoB, large trials (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009&gt;\u20092,000) with 5\u201310 year outcomes. Trials on ultra-hypofractionation and APBI focused on early stage cancer, some also including ductal carcinoma in situ (DCIS). High survival (&gt;\u200990%) and low recurrence were found across all treatments. Moderate hypofractionation probably results in less overall acute toxicity, but makes little to no difference in specific adverse events. No trial on ultra-hypofractionation reported overall toxicity; evidence on acute skin toxicity is very uncertain. APBI probably results in less overall acute toxicity, but may result in more overall late toxicity; evidence was very uncertain or showed no difference for specific events.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Radiation treatments had similar survival and recurrence. Moderate hypofractionation and APBI result in lower overall acute toxicity, but evidence is lacking for ultra-hypofractionation. For ultra-hypofractionation and APBI, future research is needed to better understand late toxicity outcomes, and whether effects may vary across settings and subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16129-5","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T02:13:52Z","timestamp":1782353632000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative efficacy and harms of adjuvant whole breast hypofractionation or external beam accelerated partial breast irradiation for treatment of breast cancer: a systematic review"],"prefix":"10.1186","volume":"26","author":[{"given":"Catherine","family":"Sowerby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kassahun","family":"Lemu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Landsteiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Ullman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maylen","family":"Anthony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Kalinowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Wilt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Duan-Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,25]]},"reference":[{"key":"16129_CR1","unstructured":"Wild C, Weiderpass E, Stewart B. World Cancer Report: Cancer Research for Cancer Prevention. 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK606500\/."},{"issue":"3","key":"16129_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"16129_CR3","unstructured":"American Cancer Society. Cancer Facts & Figs. 2025. Atlanta: American Cancer Society. 2025. https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/annual-cancer-facts-and-figures\/2025\/2025-cancer-facts-and-figures-acs.pdf"},{"issue":"5","key":"16129_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1097\/00006534-199910000-00013","volume":"104","author":"A Pusic","year":"1999","unstructured":"Pusic A, Thompson TA, Kerrigan CL, Sargeant R, Slezak S, Chang BW, et al. Surgical options for the early-stage breast cancer: factors associated with patient choice and postoperative quality of life. Plast Reconstr Surg. 1999;104(5):1325\u201333.","journal-title":"Plast Reconstr Surg"},{"issue":"3","key":"16129_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.breast.2010.03.003","volume":"19","author":"Y Lievens","year":"2010","unstructured":"Lievens Y. Hypofractionated breast radiotherapy: financial and economic consequences. Breast. 2010;19(3):192\u20137.","journal-title":"Breast"},{"issue":"3","key":"16129_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1754-9485.2010.02163.x","volume":"54","author":"P Dwyer","year":"2010","unstructured":"Dwyer P, Hickey B, Burmeister E, Burmeister B. Hypofractionated whole-breast radiotherapy: impact on departmental waiting times and cost. J Med Imaging Radiat Oncol. 2010;54(3):229\u201334.","journal-title":"J Med Imaging Radiat Oncol"},{"key":"16129_CR7","doi-asserted-by":"crossref","unstructured":"Hickey B, James M, Lehman M, Hider P, Jeffery M, Francis D, et al. Hypofractionated radiation therapy for early breast cancer. Cochrane Database Syst Reviews. 2016(7). https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6457862\/.","DOI":"10.1002\/14651858.CD003860.pub4"},{"key":"16129_CR8","volume-title":"Hypofractionation Radiation Therapy for Definitive Treatment of Selected Cancers: A Systematic Review","author":"A Landsteiner","year":"2023","unstructured":"Landsteiner A, Sowerby C, Ullman K, Anthony M, Kalinowski C, Ester E, et al. VA Evidence-based Synthesis Program Reports. Hypofractionation Radiation Therapy for Definitive Treatment of Selected Cancers: A Systematic Review. Washington (DC): Department of Veterans Affairs (US); 2023."},{"key":"16129_CR9","unstructured":"DistillerSR. Version 2.35. DistillerSR Inc. 2023. Accessed Jan-Nov 2022. https:\/\/www.distillersr.com\/"},{"key":"16129_CR10","unstructured":"Cochrane Methods. Risk of Bias 2 (RoB 2) tool. 2022. https:\/\/methods.cochrane.org\/risk-bias-2"},{"key":"16129_CR11","unstructured":"Schunemann H, Brozek J, Guyatt G, et al. GRADE Handbook. 2019. https:\/\/gdt.gradepro.org\/app\/handbook\/handbook.html."},{"key":"16129_CR12","unstructured":"GRADEpro GDT. GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2025. Available from gradepro.org."},{"key":"16129_CR13","doi-asserted-by":"publisher","first-page":"109818","DOI":"10.1016\/j.radonc.2023.109818","volume":"187","author":"A Le Bras","year":"2023","unstructured":"Le Bras A, Belkacemi Y, Bourgier C, Gabelle-Flandin I, Petit A, Guilbert P, et al. Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized trial. Radiotherapy and oncology. J Eur Soc Therapeutic Radiol Oncol. 2023;187:109818.","journal-title":"J Eur Soc Therapeutic Radiol Oncol"},{"issue":"10237","key":"16129_CR14","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","volume":"395","author":"A Murray Brunt","year":"2020","unstructured":"Murray Brunt A, Haviland JS, Wheatley DA, Sydenham MA, Alhasso A, Bloomfield DJ, et al. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. Lancet (London England). 2020;395(10237):1613\u201326.","journal-title":"Lancet (London England)"},{"key":"16129_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.breast.2020.12.009","volume":"55","author":"H Van Hulle","year":"2021","unstructured":"Van Hulle H, Vakaet V, Monten C, Deseyne P, Schoepen M, Colman C, et al. Acute toxicity and health-related quality of life after accelerated whole breast irradiation in 5 fractions with simultaneous integrated boost. Breast (Edinburgh Scotland). 2021;55:105\u201311.","journal-title":"Breast (Edinburgh Scotland)"},{"issue":"5","key":"16129_CR16","first-page":"282","volume":"59","author":"A Shahid","year":"2009","unstructured":"Shahid A, Athar MA, Asghar S, Zubairi T, Murad S, Yunas N. Post mastectomy adjuvant radiotherapy in breast cancer: a comparision of three hypofractionated protocols. JPMA J Pakistan Med Association. 2009;59(5):282\u20137.","journal-title":"JPMA J Pakistan Med Association"},{"key":"16129_CR17","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.radonc.2022.07.003","volume":"174","author":"S Chakraborty","year":"2022","unstructured":"Chakraborty S, Chatterjee S. HYPORT adjuvant acute toxicity and patient dosimetry quality assurance results - Interim analysis. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2022;174:59\u201368.","journal-title":"Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol"},{"key":"16129_CR18","doi-asserted-by":"crossref","unstructured":"Ivanov O, Milovancev A, Petrovic B, Prvulovic Bunovic N, Licina J, Bojovic M, et al. Ultra-Hypofractionated vs. Moderate Fractionated Whole Breast Three Dimensional Conformal Radiotherapy during the COVID-19 Pandemic. Medicina (Kaunas, Lithuania). 2022;58(6). https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9231223\/.","DOI":"10.3390\/medicina58091306"},{"issue":"4","key":"16129_CR19","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.ijrobp.2023.10.018","volume":"118","author":"BS Laughlin","year":"2024","unstructured":"Laughlin BS, Corbin KS, Toesca DAS, Thorpe CS, Golafshar MA, Pockaj B, et al. Physician- and Patient-Reported Outcomes of the MC1635 Phase 3 Trial of Ultrahypofractionated Versus Moderately Hypofractionated Adjuvant Radiation Therapy After Breast-Conserving Surgery. Int J Radiat Oncol Biol Phys. 2024;118(4):1049\u201359.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"16129_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.radonc.2011.06.026","volume":"100","author":"RK Agrawal","year":"2011","unstructured":"FAST Trialists Group, Agrawal RK, Alhasso A, Barrett-Lee PJ, Bliss JM, Bliss P, et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE\/04\/015). Radiotherapy and oncology. J Eur Soc Therapeutic Radiol Oncol. 2011;100(1):93\u2013100.","journal-title":"J Eur Soc Therapeutic Radiol Oncol"},{"issue":"5","key":"16129_CR21","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/0360-3016(90)90216-7","volume":"19","author":"F Baillet","year":"1990","unstructured":"Baillet F, Housset M, Maylin C, Boisserie G, Bettahar R, Delanian S, et al. The use of a specific hypofractionated radiation therapy regimen versus classical fractionation in the treatment of breast cancer: a randomized study of 230 patients. Int J Radiat Oncol Biol Phys. 1990;19(5):1131\u20133.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"16129_CR22","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.adro.2019.09.005","volume":"5","author":"BS Yadav","year":"2020","unstructured":"Yadav BS, Loganathan S, Sharma SC, Singh R, Dahiya D. Comparison of Toxicity and Cosmetic Outcomes After Accelerated Partial Breast Irradiation or Whole Breast Irradiation Using 3-Dimensional Conformal External Beam Radiation Therapy. Adv Radiation Oncol. 2020;5(2):171\u20139.","journal-title":"Adv Radiation Oncol"},{"issue":"1","key":"16129_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13014-024-02412-x","volume":"19","author":"P Burkon","year":"2024","unstructured":"Burkon P, Selingerova I, Slavik M, Holanek M, Vrzal M, Coufal O, et al. Toxicity of external beam accelerated partial-breast irradiation (APBI) in adjuvant therapy of early-stage breast cancer: prospective randomized study. Radiation Oncol (London England). 2024;19(1):17.","journal-title":"Radiation Oncol (London England)"},{"issue":"10215","key":"16129_CR24","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/S0140-6736(19)32515-2","volume":"394","author":"TJ Whelan","year":"2019","unstructured":"Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, et al. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019;394(10215):2165\u201372.","journal-title":"Lancet"},{"issue":"4","key":"16129_CR25","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ejca.2014.12.013","volume":"51","author":"L Livi","year":"2015","unstructured":"Livi L, Meattini I, Simontacchi G, Paiar F, Scotti V, De Luca Cardillo C, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015;51(4):451\u201363.","journal-title":"Eur J Cancer"},{"issue":"5","key":"16129_CR26","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/j.ijrobp.2013.08.046","volume":"87","author":"N Rodriguez","year":"2013","unstructured":"Rodriguez N, Sanz X, Dengra J, Foro P, Membrive I, Reig A, et al. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2013;87(5):1051\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"16129_CR27","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s12094-021-02618-5","volume":"23","author":"X Li","year":"2021","unstructured":"Li X, Sanz J, Foro P, Martinez A, Zhao M, Reig A, et al. Long-term results of a randomized partial irradiation trial compared to whole breast irradiation in the early stage and low-risk breast cancer patients after conservative surgery. Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico. 2021;23(10):2127\u201332.","journal-title":"Clin translational oncology: official publication Federation Span Oncol Soc Natl Cancer Inst Mexico"},{"issue":"7","key":"16129_CR28","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1001\/jamaoncol.2015.2666","volume":"1","author":"SF Shaitelman","year":"2015","unstructured":"Shaitelman SF, Schlembach PJ, Arzu I, Ballo M, Bloom ES, Buchholz D, et al. Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. JAMA Oncol. 2015;1(7):931\u201341.","journal-title":"JAMA Oncol"},{"issue":"35","key":"16129_CR29","doi-asserted-by":"publisher","first-page":"3495","DOI":"10.1200\/JCO.18.00317","volume":"36","author":"SF Shaitelman","year":"2018","unstructured":"Shaitelman SF, Lei X, Thompson A, Schlembach P, Bloom ES, Arzu IY, et al. Three-year outcomes with hypofractionated versus conventionally fractionated whole-breast irradiation: Results of a randomized, noninferiority clinical trial. J Clin Oncol. 2018;36(35):3495\u2013503.","journal-title":"J Clin Oncol"},{"issue":"31","key":"16129_CR30","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1200\/JCO.20.01363","volume":"38","author":"BV Offersen","year":"2020","unstructured":"Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, et al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin oncology: official J Am Soc Clin Oncol. 2020;38(31):3615\u201325.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"5","key":"16129_CR31","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1470-2045(20)30085-1","volume":"21","author":"MT King","year":"2020","unstructured":"King MT, Link EK, Whelan TJ, Olivotto IA, Kunkler I, Westenberg AH, et al. Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3\u201307\/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(5):685\u201398.","journal-title":"Lancet Oncol"},{"key":"16129_CR32","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.radonc.2020.02.018","volume":"146","author":"LC Schmeel","year":"2020","unstructured":"Schmeel LC, Koch D, Schmeel FC, Rohner F, Schoroth F, Bucheler BM, et al. Acute radiation-induced skin toxicity in hypofractionated vs. conventional whole-breast irradiation: An objective, randomized multicenter assessment using spectrophotometry. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2020;146:172\u20139.","journal-title":"Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol"},{"issue":"6","key":"16129_CR33","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1056\/NEJMoa0906260","volume":"362","author":"TJ Whelan","year":"2010","unstructured":"Whelan TJ, Pignol J-P, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010;362(6):513\u201320.","journal-title":"N Engl J Med"},{"issue":"15","key":"16129_CR34","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1093\/jnci\/94.15.1143","volume":"94","author":"T Whelan","year":"2002","unstructured":"Whelan T, MacKenzie R, Julian J, Levine M, Shelley W, Grimard L, et al. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst. 2002;94(15):1143\u201350.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"16129_CR35","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.ijrobp.2020.03.049","volume":"107","author":"J Arsenault","year":"2020","unstructured":"Arsenault J, Parpia S, Goldberg M, Rakovitch E, Reiter H, Doherty M, et al. Acute Toxicity and Quality of Life of Hypofractionated Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2020;107(5):943\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16129_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.breast.2023.02.005","volume":"68","author":"M Goldberg","year":"2023","unstructured":"Goldberg M, Parpia S, Rakovitch E, Chang L, Bowen J, Lukka H, et al. Long-term outcomes and effects of hypofractionated radiotherapy in microinvasive breast cancer: Analysis from a randomized trial. Breast (Edinburgh Scotland). 2023;68:189\u201393.","journal-title":"Breast (Edinburgh Scotland)"},{"issue":"3","key":"16129_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/S1470-2045(18)30813-1","volume":"20","author":"S-L Wang","year":"2019","unstructured":"Wang S-L, Fang H, Song Y-W, Wang W-H, Hu C, Liu Y-P, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2019;20(3):352\u201360.","journal-title":"Lancet Oncol"},{"issue":"5","key":"16129_CR38","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ijrobp.2012.10.034","volume":"85","author":"JK Weng","year":"2013","unstructured":"Weng JK, Lei X, Schlembach P, et al. Phase 1 clinical trial of stereotactic body radiation therapy concomitant with neoadjuvant chemotherapy for breast cancer. Int J Radiat Oncol Biol Phys. 2013;85(5):1193\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"31","key":"16129_CR39","doi-asserted-by":"publisher","first-page":"3604","DOI":"10.1200\/JCO.20.01024","volume":"38","author":"S-L Wang","year":"2020","unstructured":"Wang S-L, Fang H, Hu C, Song Y-W, Wang W-H, Jin J, et al. Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial From China. J Clin oncology: official J Am Soc Clin Oncol. 2020;38(31):3604\u201314.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"4","key":"16129_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","volume":"9","author":"SM Bentzen","year":"2008","unstructured":"START Trialists Group, Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol. 2008;9(4):331\u201341.","journal-title":"Lancet Oncol"},{"issue":"11","key":"16129_CR41","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","volume":"14","author":"JS Haviland","year":"2013","unstructured":"Haviland JS, Owen JR, Dewar JA, Agrawal RK, Barrett J, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 2013;14(11):1086\u201394.","journal-title":"Lancet Oncol"},{"issue":"9618","key":"16129_CR42","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/S0140-6736(08)60348-7","volume":"371","author":"SM Bentzen","year":"2008","unstructured":"START Trialists Group, Bentzen SM, Agrawal RK, Aird EGA, Barrett JM, Barrett-Lee PJ, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet (London England). 2008;371(9618):1098\u2013107.","journal-title":"Lancet (London England)"},{"issue":"6","key":"16129_CR43","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S1470-2045(06)70699-4","volume":"7","author":"JR Owen","year":"2006","unstructured":"Owen JR, Ashton A, Bliss JM, Homewood J, Harper C, Hanson J, et al. Effect of radiotherapy fraction size on tumour control in patients with early-stage breast cancer after local tumour excision: long-term results of a randomised trial. Lancet Oncol. 2006;7(6):467\u201371.","journal-title":"Lancet Oncol"},{"key":"16129_CR44","doi-asserted-by":"crossref","unstructured":"Spooner D, Stocken DD, Jordan S, Bathers S, Dunn JA, Jevons C et al. A randomised controlled trial to evaluate both the role and the optimal fractionation of radiotherapy in the conservative management of early breast cancer. Clinical oncology (Royal College of Radiologists (Great Britain)). 2012;24(10):697\u2013706.","DOI":"10.1016\/j.clon.2012.08.003"},{"key":"16129_CR45","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/1748-717X-7-80","volume":"7","author":"H Van Parijs","year":"2012","unstructured":"Van Parijs H, Miedema G, Vinh-Hung V, Verbanck S, Adriaenssens N, Kerkhove D, et al. Short course radiotherapy with simultaneous integrated boost for stage I-II breast cancer, early toxicities of a randomized clinical trial. Radiation Oncol (London England). 2012;7:80.","journal-title":"Radiation Oncol (London England)"},{"key":"16129_CR46","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/1471-2407-12-495","volume":"12","author":"H Versmessen","year":"2012","unstructured":"Versmessen H, Vinh-Hung V, Van Parijs H, Miedema G, Voordeckers M, Adriaenssens N, et al. Health-related quality of life in survivors of stage I-II breast cancer: randomized trial of post-operative conventional radiotherapy and hypofractionated tomotherapy. BMC Cancer. 2012;12:495.","journal-title":"BMC Cancer"},{"key":"16129_CR47","doi-asserted-by":"publisher","first-page":"1211544","DOI":"10.3389\/fonc.2023.1211544","volume":"13","author":"H Van Parijs","year":"2023","unstructured":"Van Parijs H, Cecilia-Joseph E, Gorobets O, Storme G, Adriaenssens N, Heyndrickx B, et al. Lung-heart toxicity in a randomized clinical trial of hypofractionated image guided radiation therapy for breast cancer. Front Oncol. 2023;13:1211544.","journal-title":"Front Oncol"},{"issue":"28","key":"16129_CR48","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1200\/JCO.19.02750","volume":"38","author":"AM Brunt","year":"2020","unstructured":"Brunt AM, Haviland JS, Sydenham M, Agrawal RK, Algurafi H, Alhasso A, et al. Ten-Year Results of FAST: A Randomized Controlled Trial of 5-Fraction Whole-Breast Radiotherapy for Early Breast Cancer. J Clin oncology: official J Am Soc Clin Oncol. 2020;38(28):3261\u201372.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"1","key":"16129_CR49","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.radonc.2016.02.027","volume":"120","author":"AM Brunt","year":"2016","unstructured":"Brunt AM, Wheatley D, Yarnold J, Somaiah N, Kelly S, Harnett A, et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol. 2016;120(1):114\u20138.","journal-title":"Radiotherapy oncology: J Eur Soc Therapeutic Radiol Oncol"},{"issue":"3","key":"16129_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10549-015-3565-2","volume":"153","author":"I Meattini","year":"2015","unstructured":"Meattini I, Di Brina L, Mangoni M, Meacci F, Francolini G, Desideri I, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy technique compared to whole breast irradiation for patients aged 70 years or older: subgroup analysis from a randomized phase 3 trial. Breast Cancer Res Treat. 2015;153(3):539\u201347.","journal-title":"Breast Cancer Res Treat"},{"issue":"35","key":"16129_CR51","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1200\/JCO.20.00650","volume":"38","author":"I Meattini","year":"2020","unstructured":"Meattini I, Lucidi S, Marrazzo L, Desideri I, Scotti V, Simontacchi G, et al. Accelerated partial-breast irradiation compared with whole-breast irradiation for early breast cancer: Long-term results of the randomized phase III APBI-IMRT-florence trial. J Clin Oncol. 2020;38(35):4175\u201383.","journal-title":"J Clin Oncol"},{"issue":"32","key":"16129_CR52","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.1200\/JCO.2013.50.5511","volume":"31","author":"IA Olivotto","year":"2013","unstructured":"Olivotto IA, Berrang T, Truong PT, Beckham W, Nichol A, Reed M, et al. Interim cosmetic and toxicity results from RAPID: A randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31(32):4038\u201345.","journal-title":"J Clin Oncol"},{"issue":"2","key":"16129_CR53","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.ijrobp.2021.05.004","volume":"111","author":"JK Weng","year":"2021","unstructured":"Weng JK, Lei X, Schlembach P, Bloom ES, Shaitelman SF, Arzu IY, et al. Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2021;111(2):360\u201370.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"16129_CR54","doi-asserted-by":"publisher","first-page":"753209","DOI":"10.3389\/fonc.2021.753209","volume":"11","author":"L Gu","year":"2021","unstructured":"Gu L, Dai W, Fu R, Lu H, Shen J, Shi Y, et al. Comparing Hypofractionated With Conventional Fractionated Radiotherapy After Breast-Conserving Surgery for Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials. Front Oncol. 2021;11:753209.","journal-title":"Front Oncol"},{"key":"16129_CR55","doi-asserted-by":"publisher","first-page":"e079089","DOI":"10.1136\/bmj-2023-079089","volume":"386","author":"SF Lee","year":"2024","unstructured":"Lee SF, Kennedy SKF, Caini S, Wong HCY, Yip PL, Poortmans PM, et al. Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis. BMJ. 2024;386:e079089.","journal-title":"BMJ"},{"key":"16129_CR56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.breast.2022.01.018","volume":"62","author":"GN Marta","year":"2022","unstructured":"Marta GN, Riera R, Pacheco RL, Cabrera Martimbianco AL, Meattini I, Kaidar-Person O, et al. Moderately hypofractionated post-operative radiation therapy for breast cancer: Systematic review and meta-analysis of randomized clinical trials. Breast. 2022;62:84\u201392.","journal-title":"Breast"},{"issue":"3","key":"16129_CR57","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","volume":"8","author":"BD Smith","year":"2018","unstructured":"Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Practical Radiation Oncol. 2018;8(3):145\u201352.","journal-title":"Practical Radiation Oncol"},{"key":"16129_CR58","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.breast.2019.08.001","volume":"48","author":"TRM Andrade","year":"2019","unstructured":"Andrade TRM, Fonseca MCM, Segreto HRC, Segreto RA, Martella E, Nazario ACP. Meta-analysis of long-term efficacy and safety of hypofractionated radiotherapy in the treatment of early breast cancer. Breast J. 2019;48:24\u201331.","journal-title":"Breast J"},{"issue":"3","key":"16129_CR59","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10549-017-4118-7","volume":"162","author":"LF Valle","year":"2017","unstructured":"Valle LF, Agarwal S, Bickel KE, Herchek HA, Nalepinski DC, Kapadia NS. Hypofractionated whole breast radiotherapy in breast conservation for early-stage breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2017;162(3):409\u201317.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"16129_CR60","first-page":"Cd007077","volume":"8","author":"BE Hickey","year":"2021","unstructured":"Hickey BE, Lehman M. Partial breast irradiation versus whole breast radiotherapy for early breast cancer. Cochrane Database Syst Rev. 2021;8(8):Cd007077.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"16129_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-023-07112-w","volume":"203","author":"LV Ravani","year":"2024","unstructured":"Ravani LV, Calomeni P, Wang M, Deng D, Speers C, Zaorsky NG, et al. Comparison of partial-breast irradiation and intraoperative radiation to whole-breast irradiation in early-stage breast cancer patients: a Kaplan-Meier-derived patient data meta-analysis. Breast Cancer Res Treat. 2024;203(1):1\u201312.","journal-title":"Breast Cancer Res Treat"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16129-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16129-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16129-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:27:18Z","timestamp":1789532838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16129-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,25]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16129"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16129-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,25]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1102"}}